Work

A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)

Year: 2006

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2006.24.18_suppl.3015

Authors: C. P. Lee, N. J. Taylor, G. Attard, P. D. Nathan, J. S. De Bono, G. Temple, A. Tang, A. R. Padhani, I. R. Judson, G. J. Rustin

Institutions: Mount Vernon Cancer Centre, Royal Marsden Hospital

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2282484382

Cites:

Cited by: 20

Related to: 10